{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:28Z","timestamp":1790655088898,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jacc.2021.04.079","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T10:42:36Z","timestamp":1621248156000},"page":"142-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":142,"title":["Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes"],"prefix":"10.1016","volume":"78","author":[{"given":"Gerasimos","family":"Filippatos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Tasto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.04.079_bib1","doi-asserted-by":"crossref","first-page":"E886","DOI":"10.21037\/jtd.2016.09.13","article-title":"Atrial fibrillation: review of current treatment strategies","volume":"8","author":"Xu","year":"2016","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jacc.2021.04.079_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.04.079_bib3","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.111.020982","article-title":"Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study","volume":"123","author":"Alonso","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.04.079_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-019-0983-1","article-title":"Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study","volume":"19","author":"Seyed Ahmadi","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2021.04.079_bib5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3389\/fphys.2018.01726","article-title":"Chronic kidney disease increases atrial fibrillation inducibility: involvement of inflammation, atrial fibrosis, and connexins","volume":"9","author":"Qiu","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacc.2021.04.079_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fphys.2019.00135","article-title":"The association between diabetes mellitus and atrial fibrillation: clinical and mechanistic insights","volume":"10","author":"Bohne","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacc.2021.04.079_bib7","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jacc.2017.07.755","article-title":"Care patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT-AF registry","volume":"70","author":"Echouffo-Tcheugui","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.079_bib8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review","volume":"69","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2021.04.079_bib9","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.04.079_bib10","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","article-title":"The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation","volume":"289","author":"Lavall","year":"2014","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2021.04.079_bib11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacc.2009.09.045","article-title":"Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation","volume":"55","author":"Tsai","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.079_bib12","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart\u00a0Failure) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.079_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40256-019-00353-5","article-title":"Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial","volume":"20","author":"Neefs","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2021.04.079_bib14","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.04.079_bib15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.04.079_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jacc.2021.04.079_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2021.04.079_bib19","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1074\/jbc.M116.764449","article-title":"Rac1 GTPase regulates 11beta hydroxysteroid dehydrogenase type 2 and fibrotic remodeling","volume":"292","author":"Lavall","year":"2017","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2021.04.079_bib20","article-title":"Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care","volume":"6","author":"Lane","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.04.079_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","article-title":"SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials","volume":"19","author":"Li","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2021.04.079_bib22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12933-020-01162-w","article-title":"The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors","volume":"19","author":"Ling","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2021.04.079_bib23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.04.079_bib24","first-page":"640","article-title":"Atrial myopathy","volume":"4","author":"Shen","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Sci"},{"key":"10.1016\/j.jacc.2021.04.079_bib25","article-title":"The management of atrial fibrillation in heart failure: an expert panel consensus","author":"Farmakis","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2021.04.079_bib26","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ejhf.1688","article-title":"Left atrial myopathy in heart failure with preserved ejection fraction","volume":"22","author":"Reddy","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.04.079_bib27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jamacardio.2020.0136","article-title":"Therapeutic targeting of left atrial myopathy in atrial fibrillation and heart failure with preserved ejection fraction","volume":"5","author":"Patel","year":"2020","journal-title":"JAMA Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721049664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721049664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:43:23Z","timestamp":1760017403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721049664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0735109721049664"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.04.079","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.04.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}